• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.69% Nasdaq Up0.44%

    More On COT.V



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Critical Outcome Technologies Inc. (COT.V)

    0.28 Down 0.01(1.75%) 3:53PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Critical Outcome Technologies Inc.
    The Stiller Centre
    Suite 213
    London, ON N6G 4X8
    Canada - Map
    Phone: 519-858-5157
    Fax: 519-858-5179
    Website: http://www.criticaloutcome.com

    Index Membership:N/A
    Full Time Employees:6

    Business Summary 

    Critical Outcome Technologies Inc., a bioinformatics company, is engaged in the discovery and development of small molecules. The company focuses on applying CHEMSAS, a proprietary computer based technology, which identifies, profiles, optimizes, selects, and validates commercially viable drug candidates at the discovery stage of preclinical drug development. It focuses on developing drug candidates for the treatment of various cancers, such as acute myelogenous leukemia, small cell lung, ovarian, endometrial, pancreatic, brain, breast, and colorectal cancers, as well as HIV, multiple sclerosis, Alzheimer’s disease, and methicillin-resistant staphylococcus aureus. Its lead oncology compound is COTI-2, a molecule in Phase I clinical trial. The company is also engaged in the development of Rosalind, which provides personalized oncology drug treatment recommendations to physicians and patients based on the genetic profile of each individual patient’s specific cancer. Critical Outcome Technologies Inc. is headquartered in London, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Critical Outcome Technologies Inc.

    Key Executives 
    Mr. John C. Drake LLB, 67
    Exec. Chairman, Sr. Advisor and Member of The Bus. Advisory Board
    Dr. Wayne R. Danter M.D., FRCPC,
    Co-Founder, Chief Exec. Officer, Pres, Chief Scientific Officer, Non-Independent Director and Chairman of Scientific Advisory Committee
    Dr. Kathleen A. Ferguson M.D., FRCPC,
    Co-Founder, Treasurer, Sec. and Member of Compensation Committee
    Mr. Eugene Francis Kelly ,
    Chief Financial Officer
    Mr. Michael Barr ,
    VP of Marketing and Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.